Guselkumab - Janssen Biotech
Alternative Names: CNTO-1959; TREMFYA; TREMFYA ONE-PRESSLatest Information Update: 03 Jul 2024
At a glance
- Originator MorphoSys
- Developer Janssen Biotech; Janssen Pharmaceutical KK; Janssen Research & Development; Janssen-Cilag; MorphoSys; Taiho Pharmaceutical
- Class Anti-inflammatories; Antineoplastics; Antipsoriatics; Antirheumatics; Immunotherapies; Monoclonal antibodies; Skin disorder therapies; Urologics
- Mechanism of Action Interleukin-23 subunit p19 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Erythrodermic psoriasis; Palmoplantar pustulosis; Plaque psoriasis; Psoriatic arthritis; Pustular psoriasis
- Preregistration Crohn's disease; Ulcerative colitis
- Phase III Psoriasis
- Phase II Giant cell arteritis; Hidradenitis suppurativa; Lupus nephritis; Systemic scleroderma
- Phase I Familial adenomatous polyposis
- Discontinued Coeliac disease; Rheumatoid arthritis